Ronnie Shapira-Frommer, MD

home / authors / ronnie-shapira-frommer-md

Articles

Ronnie Shapira-Frommer, MD, Discusses Multidisciplinary Care to Treat Gynecologic Malignancies

Ronnie Shapira-Frommer, MD, Discusses Multidisciplinary Care to Treat Gynecologic Malignancies

April 12th 2021

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about her thoughts on the effect of the conference content across multidisciplinary specialties.

Ronnie Shapira-Frommer, MD, on Next Steps for Exploring Pembrolizumab Monotherapy in Patients With Vulvar Squamous Cell Carcinoma

Ronnie Shapira-Frommer, MD, on Next Steps for Exploring Pembrolizumab Monotherapy in Patients With Vulvar Squamous Cell Carcinoma

April 7th 2021

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about patients with vulvar cancer who were treated with pembrolizumab monotherapy.

Ronnie Shapira-Frommer, MD, on Characteristics of Responders With Vulvar Squamous Cell Carcinoma Treated on the KEYNOTE-158 Trial

Ronnie Shapira-Frommer, MD, on Characteristics of Responders With Vulvar Squamous Cell Carcinoma Treated on the KEYNOTE-158 Trial

April 5th 2021

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about patients with vulvar cancer who were responders to pembrolizumab monotherapy.

Ronnie Shapira-Frommer, MD, on Results From the KEYNOTE-158 Trial in Patients With Vulvar Squamous Cell Carcinoma

Ronnie Shapira-Frommer, MD, on Results From the KEYNOTE-158 Trial in Patients With Vulvar Squamous Cell Carcinoma

April 3rd 2021

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about a cohort of patients with vulvar cancer treated with pembrolizumab monotherapy.

Ronnie Shapira-Frommer, MD, on the Rationale for the KEYNOTE-158 Trial in Patients With Vulvar Squamous Cell Carcinoma

Ronnie Shapira-Frommer, MD, on the Rationale for the KEYNOTE-158 Trial in Patients With Vulvar Squamous Cell Carcinoma

April 1st 2021

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about data focusing on a cohort of patients with vulvar cancer treated with pembrolizumab monotherapy.